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Abstract
Background: Aquaporin-4 (AQP4) constitutes the principal water channel in the brain and is clusteredat the perivascular
astrocyte endfeet. This specific distribution of AQP4 plays a major role in maintaining water homeostasis in the brain. A
growing body of evidence points to a role ofthe dystroglycan complex and its interaction with perivascular laminin in the
clusteringof AQP4 atperivascular astrocyte endfeet. Indeed, mice lacking components of this complex or in which laminin-
dystroglycan interaction is disrupted show a delayed onset of brain edema due to a redistribution of AQP4 away from
astrocyte endfeet. It is therefore important to identify inhibitory drugs of laminin-dependent AQP4 clustering which may
prevent or reduce brain edema.
Methodolgy/Principal Findings: In the present study we used primary rat astrocyte cultures toscreen a library of .3,500
chemicals and identified 6 drugs that inhibit the laminin-induced clustering of dystroglycan and AQP4. Detailed analysis of
the inhibitory drug, chloranil, revealed that its inhibition of the clustering is due to the metalloproteinase-2-mediated ß-
dystroglycan shedding and subsequent loss of laminin interaction with dystroglycan. Furthermore, chemical variants of
chloranil induced a similar effect on ß-dystroglycan and this was prevented by the antioxidant N-acetylcysteine.
Conclusion/Significance: These findings reveal the mechanism of action of chloranil in preventing the laminin-induced
clustering of dystroglycan and AQP4 and validate the use of high-throughput screening as a tool to identify drugs that
modulate AQP4 clustering and that could be tested in models of brain edema.
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Introduction
Cerebral edema with excess accumulation of water and cellular
swelling is a common consequence of stroke, traumatic brain
injury, brain tumor and meningitis. In the normal brain, water is
distributed between cerebrospinal fluid, blood, intracellular and
interstitial compartments and moves between these compartments
in response to osmotic gradients. In pathological conditions, the
abnormal accumulation of water in brain parenchyma gives rise to
either cytotoxic or vasogenic edema [1]. Cytotoxic edema is seen
in early cerebral ischemia and is primarily characterized by an
increase in astrocyte volume due to enhanced water flux from the
bloodstream into these cells. Vasogenic edema is often seen
following brain tumor formation and is characterized by enhanced
water entry in the interstitial compartment of the brain due to the
disruption of the blood-brain barrier [1].
Aquaporin-4 (AQP4), the principal water channel in the brain,
is mainly expressed at the interface between the brain tissue and
the blood at the perivascular astrocyte endfeet [2]. Recent studies
in the AQP4 knockout or overexpressing mice demonstrated a
dual role for AQP4 in the pathophysiology of brain edema
[1,3,4,5,6,7]. Indeed, there is increasing evidence that AQP4
deficiency is associated with reduced water entry into the brain
and reduced water outflow from the brain parenchyma in edema
models that include water intoxication, focal cerebral ischemia,
bacterial meningitis, cortical freeze-injury and brain tumor [1,4].
Because AQP4 permits bidirectional water transport it has been
shown that it plays a role not only in the early accumulation of
water in cytotoxic edema [4] but also in the removal of excess
water in vasogenic edema [1,8,9,10]. Therefore, blocking AQP4
or inhibiting its clustering around blood vessels would reduce
water entry which may be beneficial in preventing cytotoxic
edema at early stages of stroke. On the contrary, activating AQP4
or increasing its clustering around blood vessels would promote the
extrusion of the excess water from the brain preventing thereby
vasogenic edema.
Several studies have focused their effort in designing drugs that
specifically inhibit AQP4 function [11,12,13,14,15,16,17]. To
date, only three drugs, tetraethylammonium (TEA), 6-ethoxyben-
zothiazole-2-sulfamide (EZA) and acetazolamide (AZA) have been
identified as potential inhibitors of AQP4 activity. However, the
ability of these candidate blockers to inhibit cell swelling upon
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e17559hypo-osmotic chockhas been disputed [18]. In an attempt to
identify other drugs that inhibit the function of AQP4 in water
transport, Mola et al [15] developed a functional high-throughput
assay based on the measurement of osmotically-induced cell
volume changes to screen several libraries of drugs and identified
four blockers of AQP4-mediated water transport.
Multiple lines of evidence suggest that the integrity ofthe
dystroglycan complex (DGC) is essential for the properlocalization
Figure 1. Validation of the Cellomics
TM Arrayscan V
TI automated fluorescence imaging of the laminin-induced clustering of
ß-dystroglycan in primary astrocyte cultures. A. Images of untreated astrocytes and astrocytes treated with 20 nM laminin-1 were acquired on
the ArrayScan V
TI HCS Reader. The right panels are merged images of Hoechst 33342 (left panels) and ß-DG labelled astrocytes (middle panels).
Automatic identification of the cytoplamic maskof individual astrocytes(red) and detected spots (yellow) by the Compartmental Analysis
BioApplication. B, C. Dose-response curve of laminin-induced ß-DG clusteringin astrocytes grown in 96 well-plates. Each point represents the mean
number of clusters or areas of clusters 6 S.E.M. from three different experiments. Scale bar, 30 mm.
doi:10.1371/journal.pone.0017559.g001
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numerous intracellular proteins such as syntrophin, dystrobrevin
and dystrophin downstream of dystroglycan (DG) [19,20]. DG is
post-translationally cleaved into a transmembrane protein, b-DG,
and an extracellular protein, a-DG. Alpha-DG binds non-
covalently to the short extracellular domain of ß-DG as well as
to the extracellular matrix proteins laminin, agrin and perlecan as
well as neurexin [21,22,23,24]. Intracellularly, ß-DG binds
directly to dystrophin, which in turn binds dystrobrevin and
syntrophin. Interestingly, DG, dystrophin, dystrobrevin and
syntrophin are co-clustered with AQP4 at perivascular astrocyte
endfeet [25,26]. We have shown in astrocyte cultures that this co-
clusteringis mediated by the interaction of DG with extracellular
laminin-1 [27,28]. Likewise, we have demonstrated that a-DG
interaction with perivascular laminin is key to the polarized
distribution of AQP4 at astrocyte endfeet in brain [25].
Furthermore, the deletion of a-syntrophin or mutations of
dystrophinresult in the loss of AQP4 clustering, relocating it away
from astrocyte endfeet [29,30,31]. Most importantly, theloss of
AQP4 polarized distribution in thesemice resulted in a beneficial
effect as it delayed the onset of brain edema [32,33]. Therefore,
treatments using drugscapable of disrupting the clustered distri-
bution of the DGC at astrocyte endfeet will ultimately leadto the
disruption of AQP4 distributionas well.
In the present study we used a well established assay of laminin-
induced clustering of the DGC and AQP4 in primary astrocyte
cultures to screen a library of .3,500 chemicals and identified 5
enhancers and 6 inhibitorsof this clustering. Here, we focused our
analysis on chloranil,one the inhibitory drugs, anddemonstrate
that it causes cell surface cleavage of the 43 kDa ß-DGto a 31 kDa
form via a metalloproteinase-mediated mechanism. Chemical
variants of chloranil also induce ß-DG sheddingleading to the loss
of cell surface tethering of a-DG andsubsequent severance of
laminin binding,resulting in the inhibition of DG and AQP4
clustering. This study provides evidence that the DGC is a
valuable target for the disruption of laminin-induced AQP4
clustering andvalidates the high-throughput screen on primary
astrocyte cultures as a powerful tool in the discovery of potential
therapeutic drugs for both cytotoxic and vasogenic edema that
occur in brain disorders including stroke, tumour, hydrocephalus,
infection and traumatic brain injury.
Materials and Methods
Chemicals
The 3,594 chemicals used in the screen were from the
Pretswick, Sigma LOPAC, Microsource Spectrum and Biomol
natural products collections, and were provided by the Canadian
Chemical Biology Network (www.ccbn-rbc.ca). P-chloranil (re-
ferred to as chloranil in the rest of the text), benzoquinone and
flunarizine were purchased from Sigma-Aldrich and Hoechst
33342 was from Invitrogen. Prinomastat (AG3340) was purchased
from Agouron Pharmaceuticals, the tissue inhibitors of metallo-
proteinases TIMP1 and TIMP2 were a generous gift from Dr.
C.M. Overall (University of British Columbia, Vancouver)and
TIMP3was purchased from R&D Systems (Minneapolis, MN,
USA). N-acetyl-L-cysteine (NAC) was purchased from Sigma-
Aldrich.
Antibodies
The following antibodies were used: rabbit anti-AQP4 raised
against rat GST-AQP4 residues 249–323 (Alomone Laboratories,
Jerusalem, Israel), mouse anti-ß-DG, 43DAG1/8D5, raised
against 15 of the last 16 C-terminal amino acids of human
dystroglycan (Novocastra Laboratories, Newcastle-upon-tyne,
UK), mouse anti- syntrophin, SYN1351, raised against Torpedo
syntrophin (Affinity Bioreagents, USA), and mouse anti-ß-actin
raised against a mouse synthetic peptide (Sigma, USA).
Chemical screen for modulators of laminin-induced
dystroglycan clustering in astrocytes
Experiments were performed using postnatal day 1 Sprague-
Dawley rats (Charles River) in accordance with protocols (#A06-
0319)approved by the animal care committee of the University of
British Columbia. Primary hippocampal astrocyte cultures were
prepared from postnatal day 1Sprague-Dawley rats (Charles
River). Hippocampi were dissected, and meninges and choroid
plexus were removed. They were then cut into small pieces and
incubated for 25 min with trypsin (3.0 mg/ml; Gibco, Burlington,
Canada). Dissociated hippocampi were then plated in culture
flasks and grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin and 1 mM L-glutamine (Gibco) for 2–3 weeks. To
remove microglia and oligodendrocyte progenitors, the flasks were
shaken the day following the plating.
The culture medium was changed every 3 days. After
trypsinization, the cells were plated in PerkinElmer View 96-
well plates at 8000 cells per well. One day after plating, the cells
were treated for 7 h with 20 nM Engelbreth-Holm-Swarm
Sarcoma laminin-1 (Sigma-Aldrich), washed with warn phos-
phate buffered saline (PBS) and fixed with 4% (w/v) parafor-
maldehyde in 0.1 M phosphate buffer for 20 min followed by
rinsing in PBS, 3615 min. Four hours before fixation, chemicals
were transferred from stock plates (5 mM in DMSO) to each
well for a final concentration of <15 mM using a Biorobotics
Biogrid II robot equipped with a 0.7 mm diameter 96-pin tool
that adds,20 nl per well. Fixed cells were incubated for 1 h at
room temperature (20–22uC) in a solution containing 2% bovine
serum albumin (Sigma) and 0.25% Triton X-100. Immunolabel-
ling was performed by incubating the cells at room temperature
for 1 h in the presence of the primary antibody against ß-DG
(1/100). Subsequently, cells were rinsed with PBS (3615 min)
and incubated with Alexa Fluor 568 goat anti-mouse IgG (1/
200; Molecular Probes, USA). After several washes with PBS,
the cells were incubated with PBS containing 500 ng/ml
Hoechst 33342 for 15 min at room temperature. Plates were
read in a Cellomics
TM Arrayscan V
TI automated fluorescence






Z9 factor 0.54302 0.62
Signal to background 9.115798017 18.35
Signal to noise 28.62252524 35.39
Signal window 4.625771126 6.42
ß-dystroglycan clustering is a suitable assay for detection using the Cellomics
TM
Arrayscan V
TI automated fluorescence imager. ß-DG clustering in laminin-
treated astrocytes was used as the positive control and the spontaneous
clustering occurring in the absence of exogenous laminin was used as the
negative control. Z9=12((3smax+3smin)/|mmax2mmin|), where mmax is the mean
positive control signal, smax is the standard deviation of the positive control
signal, mmin is the mean negative control signal, and smin is the standard
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Hoechst and TRITC(XF-100 filter) channels. The compartment
analysis algorithm was used to identify the nuclei, apply a
cytoplasmic mask and quantitate TRITC spotsin the TRITC
channel fixed at 250 pixel intensity units. Fluorescence intensity
in the TRITC channel was gated at 10 average pixel intensity
units inside the cytoplasmic mask to select against diffuse ß-DG
staining. The total pixel intensity for clustered ß-DG was
acquired as ‘circ spot total intensity ch2’. Compounds inducing
an increase or decrease greater than 1.5 in clustered ß-DG
staining were considered as active. Wells showing 3-fold or
higher increase in clustered ß-DG staining over control were re-
examined to eliminate any false positives resulting from
precipitation of fluorescent compounds. Similarly, compounds
causing a decrease in cell number wereconsidered as toxic
chemicalsand disregarded. The Z-factor of the assay was
determined from clustered ß-DG measured in cells treated with
DMSO (negative control) or laminin (positive control). Effective
drugs identified in the screening assay were further evaluated in
a dose-response curve where DMSO concentration was kept at
0.1% in all wells for all experiments.
Cell viability assay
Cells were seeded in 96-well plates at 8000 cells per well and
grown for 24 h prior to the treatment with the drugs for 4 h as
described above. The drugs and media were then removed and
Figure 2. Identification of modulators of ß-dystroglycan clustering using a high throughput screen of a library containing 3,594
drugs. A, B. Duplicate experiments (red and green)from three 96-well plates corresponding to approximately 200 drugs are represented. Drugs
inducing a change greater than 1.6 fold in ß-DG clustering in laminin-treated compared to untreated astrocytes in both experiments (as circled in
black) were considered effective and used for subsequent testing. C, D. Normalized fold differences in the number and area of the clusters plotted for
each of the 3,594 compounds tested.
doi:10.1371/journal.pone.0017559.g002
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2.5-diphenyl-tetrazolium bromide (MTT) assay (Sigma, USA).
Cells were incubated for 2 h at 37uC with MTT, then 20%
sodium dodecyl sulfate was added and the absorbance at 570 nm
was measured after overnight incubation.
Immunoblotting
Treated astrocytes were harvested and suspended in 0.5 ml of
ice-cold extraction buffer (25 mM Tris pH 7.4, 25 mM glycine
and 150 mM NaCl) containing 1% Triton X-100, 16 complete
protease inhibitor cocktail and 5 mM EDTA. After 20 min
incubation on ice, the lysates were centrifuged at 800 g for
10 min. Supernatant was collected and the protein concentration
was quantified using a BCA protein assay kit (Pierce, USA).
Extracted proteins were denatured by boiling for 4 min in
reducing sample buffer and then loaded on 10% sodium dodecyl
sulfate-polyacrylamide electrophoresis gels. The gels were electro-
transferred to nitrocellulose membranes (Bio-Rad, Mississauga,
ON, Canada) and the blots were probed with antibodies to ß-DG
(1/300), AQP4 (1/1000), syntrophin (1/1000) andß-actin (1/
10000). Bound antibodies were detected using horseradish
peroxidase-conjugated goat anti-rabbit or goat anti-mouse IgGs
(1/2000; Jackson ImmunoResearch, USA). Signals were visualized
on Bioflex econo films (Interscience, Markham, ON, Canada)
using chemiluminescence (Amersham Biosciences, Buckingham-
shire, UK).
Gelatin zymography
Media from treated astrocytes were collected and 10 ml aliquots
per well were applied to 10% SDS-PAGE gels co-polymerized with
1% gelatin (Fisher, USA). After electrophoresis under non-reducing
conditions, the gels were washed in 2.5% Triton X-100 for 1 h to
remove SDS and then incubated for 16 h at 37uC in 20 mM Tris,
150 mM NaCl, 5 mM CaCl2 and stained with SimplyBlue
TM
Safestain (Invitrogen, USA). For the standards, we used the pre-
stained protein ladder from Bio-Rad as well as purified gelatinase A
(MMP-2) and B (MMP-9). Regions of gelatinolytic activity regions
were observed as clear bands against a blue background.
Results
Development of an automated microscopy screenfor
chemical modulators of the laminin-induced
dystroglycan clustering in primary astrocyte cultures
To screen libraries of compounds for modulators of the laminin-
induced clustering of ß-DG in primary astrocyte cultures, we used
an automated microscopy assay. The high-content screening
instrument programmed to detect and quantify fluorescent spots
enabled the automatic imaging of ß-DG fluorescent clusters on a
Cellomics ArrayScan V
TI HCS Reader and analysis by the
Compartmental Analysis BioApplication. Representative images
obtained with this automated image analysis system are shown in
Figure 1A in which each cellis outlined in red and nuclei of each
live cell overlaid in blue. Individual clusters associated with each
cell are shown in yellow (Fig. 1A). To determine the most suitable
conditions for optimum detection of ß-DG clustering in astrocytes
cultured in 96 well plates using the Cellomics reader, wetreated
these cultures with increasing concentrations of laminin-1for 7 h.
In the absence of laminin-1, ß-DG labelling was largely diffuse at
the cell surface (Fig. 1A), however in the presence of laminina
dose-dependent response both in the number and area of the
clusters was observed reaching a plateau at 20 nM of laminin-1as
previously reported in Muller glial cells (Fig. 1A–C; 21).
Evaluating assay performance. The values from untreated
negative control and treated (20 nM laminin) positive control wells
were used to assess the Z9 factor for the number of clusters and the
total area covered by the clusters per cell. The values for the
number of clusters (0.54) and the total area of clustering per cell
(0.62), are greater than 0.5, indicating that thesecriteriaare
appropriate for being used in this screening assay (Table 1). As
demonstrated by the automated assay, the addition of laminin-1
for 7 h caused a 9.11 to 18.35-fold increase in the number and
area of ß-DG clusters, respectively (Table 1). Other criteria shown
in the Table 1 include the assay’s signal/noise and signal window,
both of which are greater than 2-fold, further demonstrating the
robustness of this assay [34].
Screening of compound collections. A collection of 3,584
drugs and pharmaceutically active chemicals was tested at a
concentration of 15 mM for the final 4 h of the 7 h laminin
incubation. In addition to automatically reporting the number of
clusters and their total area, the number of cells (i.e., number of
nuclei) and the nuclear area were simultaneously measured.
Chemicals causing 80% reduction in cell number were considered
cytotoxicandwereeliminatedfromouranalysis.Compoundscausing
over 1.6-fold increase or decrease in the clustering ofß-DG without
causing cell death were considered as active (Fig. 2 C and D).
Examples of these compounds are illustrated in Figure 2A and Bin
which data compiled from three 96-well plates corresponding to
approximately 200 compounds are shown. Twelve active chemicals
were initially identified as inhibitors of the clustering,but subsequent
testing by dose-response proved that only 6 of these were true
inhibitors inducing a reduction of ß-DG clustering ranging from 2.2
to 17.1-fold (Fig. 3 and data not shown). To our knowledge, none of
these 6 compounds have been previously reported to reduce laminin-
DG interaction or laminin-induced clustering of the DGC.
Subsequent analysis has shown that two of the identified inhibitors,
namely chloranil and flunarizine, induce a dose-dependent decrease
in ß-DG clustering (Fig. 3B). To determine the most efficient
concentration of chloranil and flunarizine required to induce a 50%
inhibition (EC50) of laminin-induced clustering, astrocytes were
incubated with 20 nM laminin-1 and either chloranil of flunarizine at
concentrations ranging from 1 to 100 mM (Fig. 3B). Thedata from
thisdose-response experimentare represented as curves that were
fitted using a sigmoidal function allowing the determination of the
EC50. Figure 3B shows a dose-dependent inhibition of the laminin-
induced ß-DG clustering by both drugs, however chloranil presents
an EC50 (,20 mM) lower than that of flunarizine (,30 nM)
indicating that chloranil is more potent than flunarizine.
Characterization of the effect of chloranil and flunarizine
on ß-dystroglycan and AQP4 clustering
To assess whether AQP4 clustering is also reduced in the presence
ofchloranilandflunarizine,ß-DGandAQP4clusterswereexamined
at higherresolution bylaser confocal microscopy. The data show that
Figure 3. Dystroglycan clustering in cells treated chloranil and flunarizine dihydrochloride. A. Primary astrocytes were treated for 7 h
with 20 nM laminin-1alone, 20 nM laminin-1 and 15 mM chloranil or 20 nM laminin-1 and15 mM flunarizine during the last 4 h. The chemical
structures of chloranil and flunarizine are represented. B, C. Dose-response curve of laminin-induced ß-DG clustering in astrocytes treated with
increasing concentrations of chloranil or flunarizine (2.5 to 100 mM). Clustered staining was automatically quantified using the Cellomics ArrayScan V
TI
HCS Reader. Scale bar, 30 mm.
doi:10.1371/journal.pone.0017559.g003
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and as for ß-DG, this inhibition is dose-dependent (Fig. 4). Similar
results were found for flunarizine (data not shown).
To ensure that the reduction in ß-DG and AQP4 clustering was
not due to either cytotoxicity or reduction in ß-DG or AQP4
expression levels, we assessed cell viability using the MTT assay
Figure 4. Effect of chloranil on the laminin-induced co-clustering of ß-DG and AQP4. Primary astrocytes were treated for 7 h with 20 nM
laminin and15 mM chloranil during the last 4 h. The concentration of chloranil varied from 0 (A,B,C), 6(D,E,F), 12(G,H,I), 25 (J,K,L), 50 (M,N, O) to 100 mM
(P,Q,R). The cells were fixed and labelled for m-DG (A, D, G, J, M and P) and AQP4 (B, E, H, K, N and Q). Clustered staining was quantified using confocal
microscopy. Scale bar, 30 mm.
doi:10.1371/journal.pone.0017559.g004
Inhibitors of Dystroglycan and AQP4 Clustering
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17559andß-DG and AQP4levels by immunoblotting. Figure 5 shows
that while ß-DGexpression level remains unchanged in the
presence of flunarizine that ofAQP4is slightly decreased. Interest-
ingly, chloranil causes the cell surface cleavage of full length
43 kDa ß-DG and consequent formation of the 31 kDa fragment
of ß-DG (Fig. 5A). The size of this fragment is consistent with the
cleavage of the short extracellular domain of ß-DG that has been
reported to be mediated by metalloproteinases. We next
investigated the effectof increasing concentrations of chloranil
and flunarizine on astrocyte survival. Four hours following the
treatment with chloranil and flunarizine, we subjected the
astrocytes to the MTT cell viability assay and found that chloranil
caused a slight reduction in the total number of actrocytes but only
at a very high concentration (100 mM; Fig. 5B). These results
demonstrate that the inhibition of ß-DG and AQP4 clustering
observed with ,100 mM chloranil is not due to adverse effects on
cell survival (Fig. 3 and 4).
Chloranil-induced ß-dystroglycan shedding is mediated
by metalloproteinases
Since the formation of the 31 kDa ß-DG fragment in chloranil-
treated astrocytes is consistent with a proteolytic cleavage of ß-DG
possibly implicating metalloproteinases, we tested whether longer
exposure to chloranil results in increased accumulation of the
31 kDaß-DG. The data show a more intense 31 kDa band and
weaker 43 kDa band at 7 h compared to 4 h post-treatment
(Fig. 6). This time-dependent accumulation of the proteolytic
31 kDaß-DG fragmentisconsistent with proteolytic activity. In-
Figure 5. Effect of chloranil and flunarizine on astrocyte survival and ß-dystroglycan, and AQP4 expression. A. Primary astrocytes were
incubated for 4 h with 15 mM of active chemicals. Extracted proteins were loaded (30 mg/lane) and analyzed for ß-DG, syntrophin and AQP4
expression levels by western blot analysis. Note the 31 kDa band under the 42 kDa band corresponding to the cleaved form of ß-dystroglycan upon
chloranil treatment. B. Primary astrocytes were incubated for 4 h with different concentrations of the active chemicals. Chemicals and media were
washed away and the cells were assayed for cell viability by MTT assay.
doi:10.1371/journal.pone.0017559.g005
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withincreased chloranil concentrationsranging from 15 mMt o
50 mM(data not shown).
We next evaluated the role of metalloproteinases in the
chloranil-induced ß-DG cleavage using the metalloproteinaseinhi-
bitor, Prinomastat at 15 and 30 mM. Immunoblots of protein
extracts of astrocytes co-incubated with 15 mM chloranil and15 or
30 mM prinomastat for 7 h show that prinomastat inhibits the
chloranil-induced ß-DG cleavage partially when applied at 15 mM
and completely at 30 mM (Fig. 6). These data show conclusively
that the chloranil-induced cleavage of ß-DG is mediated by
metalloproteinases.
Shedding of ß-DG at the cell surface has been studied in many
cell types including tumor cells and glial cells. Several studies have
reported that the two metalloproteinases, MMP-2 and MMP-9
areinvolved in this processin brain [35,36]. To determine whether
chloranil-induced shedding of ß-DG in astrocytes is mediated by
these twometalloproteinases, we investigated their activity via
gelatin zymography. Culture media from untreated astrocytes and
chloranil-treated astrocytes were collected and analyzed by gelatin
zymography. As standards, we used a mix of gelatinase A (MMP-
2) and B (MMP-9) from CHO cells or purified gelatinase A. The
gelatinolytic regions observed with both untreated and chloranil-
treated astrocytes’ culture media correspond to MMP-9 and the
inactive form of MMP-2, as revealed by the clear bands at ,92
and ,72 kDa, respectively (Fig. 7A). No difference in intensity or
activation state of either one of these MMPs was observed between
the untreated and chloranil-treated astrocytes (Fig. 7A). Further
analysis was conducted using the tissue inhibitors of metallopro-
teinases, TIMP1 (110 nM), and TIMP2(100 mM) that inhibit
selectively MMP-2 and MMP-9 but not the ADAMs (a disintegrin
and a metalloproteinase) as well as TIMP3 (100 mM) that has a
broader inhibition profile which includes MMPs, the tumor
necrosis factor a-converting enzyme (TACE or ADAM17) and the
related enzyme ADAM10 [37]. Astrocytes treated for 4 h with
chloranil alone, chloranil with prinomastat or chloranil with
TIMP1, TIMP2 or TIMP3 were analyzed by immunoblotting.
Unlike prinomastat, TIMP1 did not inhibit the chloranil-induced
shedding of ß-DG (Fig. 7B). However, both TIMP2 and TIMP3
were able to inhibit this effect (Fig. 7B).
ß-dystroglycan sheddingby chloranil and its chemical
variants is mediated by reactive oxygen species
Chloranil is a general electron acceptor that has a role in radical
ion formation and has been shown to be most effective at
producingreactive oxygen species (ROS) by accepting electrons
from oxygen [38]. Based on this property of chloranil, its reported
inability to interact or regulate collagenase activity [39] and the
fact that metalloproteinases can be activated by ROS, we
hypothesized that choranil inducesß-DG shedding by producing
ROS that in turn activate specific metalloproteinases. To test this
hypothesis,astrocytes were incubated either with chloranil alone or
chloranil plus the ROS scavenger, N-acetyl-cysteine (NAC).
Interestingly, NAC completely inhibited the proteolytic cleavage
of ß-DG by chloranil (Fig. 8A).
Similar to chloranil,chemical variants of chloranil such as 2,3-
dichloro-5,6-dimethyl (1,4) benzoquinoneand benzoquinone,
induced ß-DG cell surface cleavage and a dose-dependent
decrease both in the number and area of ß-DG clusters as
assessedby immunoblotting (Fig. 8A) and immunofluorescence
analyses (Fig. 8B). The effect of chloranil and its variants is most
likely mediated by the benzoquinone which is common to these
three aromatic compounds. The observation that these variants
induce a similar effect to chloranil and that chloranil acts via the
production of ROS suggest strongly that chloranil variants
increase ROS production as well leading to the activation of
metalloproteinases.
Discussion
Several studies have supported the role of the DGC and its
interaction with extracellular laminin in the polarized distribution
of AQP4 at astrocyte endfeet abutting blood vessels. Indeed, the
severance of the DG interaction with laminin in the DG-
glycosylation deficient Large
mydmouse, results in the loss of
AQP4 localization at astrocyte endfeet without affecting its
expressionlevel [25]. We have also shown that the laminin-
induced clustering of AQP4 in astrocyte cultures requires DG
[27,28]. In addition, the deletion of a-syntrophin or mutations in
the dystrophin gene result in themislocalization of AQP4,
distributing it away from astrocyte endfeet [29,30,31]. It is
noteworthy that AQP4 mislocalization in these mice results in a
better outcome as it delays the onset of brain edema [32,40]. A
study in the AQP4-null mouse reported brain swelling in models of
vasogenic edema where excess fluid accumulates in the extracel-
lular space, due to impairment of the AQP4-dependent water
clearance [41]. On the contrary, another study in the AQP4 null
mouse reported reduced brain swelling and improved neurological
outcome following water intoxication and focal cerebral ischemia
[4]. Thisdefines a role for AQP4 in the development of cytotoxic
(cellular) cerebral edema where excess fluid accumulates mainly in
the astrocyte foot processes [4]. Modulators of AQP4 function,
expression or perivascularclusteringmay therefore have a thera-
peutic application to reduce cytotoxic edema by blocking water
influx in astrocytes at early stages of stroke. Indeed, recent studies
have identified potential inhibitors of AQP4-mediated watertran-
Figure 6. Time-dependent shedding of ß-dystroglycan by
chloranil is blocked by the metalloproteinase inhibitor,
prinomastat. Primary astrocytes were incubated with 25 mM chloranil
for 4 or 7 h with or without addition of 15 nM or 30 nM prinomastat.
Extracted proteins were loaded (30 mg/lane) and analyzed for ß-DG and
AQP4 expression levels by western blot analysis. Note the increase in
signal intensity of the 31 kDaß-DG band after extended incubation with
chloranil and its disappearance with prinomastat co-incubation.
doi:10.1371/journal.pone.0017559.g006
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have been disputed [18].
In the present study we implemented a high-throughput screen in
primary astrocyte cultures toidentifycompounds that modulate the
laminin-induced clustering of ß-DG and AQP4. First, we showed that
the CellomicsTMArrayscan VTI automated fluorescence imaging is
suitable for efficient detection of the laminin-induced clustering of ß-
D G( F i g .1 ) .I n d e e d ,t h eZ 9 factor (0.54),signal/background,signal/
noise and signal window valuesdemonstrate that the number and
area of the clusters are suitable parameters for the Cellomics-based
screening (Table 1). Screening of the Pretswick, Sigma LOPAC,
Microsource Spectrum and Biomol natural products collections
identified a number of chemically active molecules, 6 of which
inhibited ß-DG clustering. Here, we focused our study onflunarizine
Figure 7. Gelatin zymography and the effect of tissue inhibitors of metalloproteinaseson the chloranil-induced shedding of
dystroglycan. A. Primary astrocytes were incubated in the absence or the presenceof 25 mM chloranil for 7 h. Media samples were collected and
analyzed by SDS-PAGE gelatin zymography. Note the clear bands against the blue background with an apparent molecular weight of ,92 and
,72 kDa, representing gelatinolytic activity of MMP-9 and MMP-2, respectively. The chloranil does not modulate the amount of MMP-2 and 9 or their
activation state. B. Primary astrocytes were incubated for 4 h with 25 mM chloranil alone, 25 mM chloranil with 30 mMprinomastat, 25 mM chloranil
with 110 nM TIMP1, 25 mM chloranil with 100 mM TIMP2 or 25 mM chloranil with 100 mM TIMP3. Protein extracts were loaded (30 mg/lane) and
immunoblotted for ß-DG. Note that the chloranil-mediated shedding of ß-DG is inhibited by prinomastat, TIMP2and TIMP3 but not TIMP1.
doi:10.1371/journal.pone.0017559.g007
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laminin-mediated clustering. A. Primary astrocytes were incubated for 4 h with 15 mM of active chemicals. Protein extracts were loaded (30 mg/
lane) and analyzed for ß-DG expression levels by western blot analysis. Note the 31 kDa band corresponding to the cleaved form of ß-DG upon
chloranil as well as 2,3-dichloro-5,6-dimethyl-(1,4)benzoquinone or benzoquinone treatment. The chloranil induced shedding of ß-dystroglycan is
prevented by co-incubation of the cells with 15 mM of chloranil and 1 mM of the ROS scavenger, N-Acetylcysteine (NAC). B, C. Primary astrocytes were
treated for 7 h with 20 nM laminin and chloranil, 2,3-dichloro-5,6-dimethyl-(1,4)benzoquinone or benzoquinone during the last 4 h. The
concentration of the compounds varied from 2.5 to 100 mM. Clustered staining was quantified using the automated microscopy assay.
doi:10.1371/journal.pone.0017559.g008
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EC50 that chloranil (EC50,20 mM) is more potent than flunarizine
(EC50,30 mM). The effect of these drugs on ß-DG clustering was
reversible (data not shown) and neither of them compromised
astrocyte viability at the concentration used throughout the
experiments. These are generally considered favourable properties
for drugs with a therapeutic potential.
However, studies have reported that chloranil is able to generate
DNA single-strand brakes in V79 chinese Hamster cells [42] and
various levels of toxicity depending on the cell type [38,43].
Indeed, amongst several quinones tested, chloranil was the only
one to induce a weak toxicity in platelets [43] and was less toxic in
PC12 cells than in primary hepatocytes [38]. We noted minimal
toxicity on primary astrocytes at doses that induced a significant
inhibition on ß-DG and AQP4 clustering, suggesting that the
degree of chloranil toxicity is cell type-dependent.
Flunarizine plays the role of a calcium channel blocker in
astrocytes [44,45] and protects rats from severe ischemic cell death
[46]. Its role on brain edema has been investigated and despite a
remarkable recovery of the electroencephalographic activity in a
rat model of cerebral ischemia [47] and an increased recovery rate
of the electrical potential in a cat model of spinal contusion injury
[48], flunarizine did not induce a significant inhibition of brain
swelling. Furthermore, flunarizine has proven to be effective in
preventing ischemia in subarachnoid hemmorrhage, although its
effect on cerebral infarction has not been proven yet [49]. Further
in vivo experiments aiming at investigating the role of flunarizine in
models of cytotoxic brain edema addressing particularly its effect
on DG and AQP4 perivascular distribution are warranted.
Chloranil is commonly used as an oxidizing agent in organic
syntheses. Here we show that it induces the shedding ofß-DG
ectodomain resulting in the formation of the 31 kDa ß-DG
fragment and a similar effect isseenwith other oxidizing agents
such as 2,3-dichloro-5,6-dimethyl-(1,4)benzoquinoneand benzo-
quinone, suggesting that the effect of chloranil and its variants on
ß-DG is due toROS production. This is further substantiated by
the observation that chloranil-induced ß-DG shedding is prevent-
ed by the anti-oxidant, NAC (Fig. 8). ß-DG shedding is typical of a
metalloproteinase-mediated cell surface cleavage of ß-DG as
previously reported [36,50,51]. Indeed, our data show that
prinomastat, an inhibitor with selectivity for MMP-2, 9, 13, and
14,completely blocks the chloranil-induced cell surface shedding of
ß-DG (Fig. 7B). These findings together with the established role of
ROS in MMP activation [52,53,54] indicate that chloranil induces
the production of ROS that in turn activates metalloproteinases
leading to the cleavage of ß-DG ectodomain. This is in accordance
with the report that cerebral ischemia seen after oxygen-glucose
deprivation leads to a metalloproteolytic cleavage of ß-DG in
astrocytes [55] and that prinomastat protects against ischemic
brain injury as shown in hippocampal organotypic slices [56].
A number of studies have shown that ß-DG is a substrate for
MMP-2 and 9 but not MMP-3, 8 or 13 [36,50,57,58,59]. Our
data showing a lack of inhibition of the chloranil effect by TIMP1
argue against an MMP-9-mediated ß-DG shedding (Fig. 7B).
However, the fact that both TIMP2 and 3 inhibit the chloranil-
induced ß-DG shedding indicate that MMP-2 is one of the
metalloproteinases targeted by chloranil. Although TIMP3 has the
ability to inhibit not only gelatinases including MMP-2 but also the
tumor necrosis factor-a (TNF-a)-containing enzyme (TACE or
ADAM17) and the related enzyme ADAM10 [60], ADAM17 and
10 are unlikely targets of chloranil since prinomastat, which is a
potent inhibitor of MMP-2 [61] but not ADAMs can completely
inhibit the chloranil-induced ß-DG shedding. This, together with
the TIMP2 inhibition, supports further the implication of MMP-2
in the chloranil-induced effect. It is noteworthy that the pro-
MMP-2 (inactive MMP2; Fig. 7A) but not the active MMP-2 is
detected in the culture medium harvested from astrocytes treated
with chloranil, as reflected by the gelatine zymography assay. It is
therefore possible that the activation of MMP-2 by chloranil
occurs at or near the cell membrane where membrane-type MMPs
(MT-MMPs) play a role in tethering MMP activity [62], which
would explain the absence of active MMP2 in the culture medium.
This suggests that TIMP2 and TIMP3 inhibition of MMP-2
activation by chloranil occurs at the cell surface. Indeed,mem-
brane-bound pro-MMP2 processing is inhibited in the presence of
high concentrations of TIMP2 [63] and TIMP3 [64].
In light of the fact that ROS-induced activation of MMPs is
involved in blood brain barrier (BBB) disruption leading to
vasogenic edema after stroke [65], the use of chloranil would be
deleterious as it would result in the breakdown of the BBB. While
the detailed analysis of chloranil allows its elimination as a
potential drug that could be used in models of brain edema,
several other drugs that inhibit both ß-DG and AQP4 clustering in
a metalloproteinase-independent manner have been identified in
the present study using the high throughput screen on primary
astrocyte cultures. Further investigations will determine the
effectiveness of these drugs in reducing the clustering of ß-DG
and AQP4 at perivascular astrocyte endfeet in vivo and in
preventing cytotoxic brain edema.
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